⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401088 | 0.91 | — | — | |
| SCHEMBL401144 | 0.84 | — | — | |
| SCHEMBL399408 | 0.83 | KDM4E (0.32) | — | |
| SCHEMBL4066003 | 0.81 | — | — | |
| SCHEMBL402700 | 0.80 | — | — | |
| SCHEMBL397034 | 0.79 | — | — | |
| SCHEMBL401154 | 0.77 | NPC1 (0.33) | — | |
| SCHEMBL4071578 | 0.75 | — | — | |
| SCHEMBL4064132 | 0.73 | — | — | |
| SCHEMBL4061865 | 0.73 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008076143-A1 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | WO | claimed |
| EP-1979002-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI Pharmaceuticals, Inc. (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007075554-A2 | COMBINATION OF IGFR INHIBITOR AND ANTI-CANCER AGENT | OSI PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |